Skip to main content

Literature reviews and economic model for COVID-19

Our team conducted literature reviews for the input of an economic model for COVID-19

What we did

Project background

A global pharmaceutical company specializing in vaccines wanted to prove the economic value of their newly developed COVID-19 vaccine. They needed a cost-effectiveness model comparing their vaccine to those currently in use, along with an economic systematic literature review (SLR) to support the model and provide information to discover a niche for their product.

Challenges faced

The rapidly changing landscape of COVID-19 posed several challenges. By the time the economic SLR was finished, the information had already become outdated. Most of the articles considered initial COVID-19 vaccinations, while booster vaccinations were more relevant. In addition, new variants of COVID-19 were not researched in the identified articles.

Our solution

To address these challenges, we supplemented the SLR with a targeted literature review (TLR), which we updated while writing the report. This approach ensured that the latest and most relevant data was available in the report, even if it had not been identified in the SLR.

Our impact

The client was satisfied with the results, especially with the economic model and with the accuracy of the TLR. This success led to a follow-up project: an NMA on adverse events related to COVID-19 vaccines.

Meet the experts

Bert Wolters, MSc

Bert Wolters, MSc

Gabriel Gurgel, MSc

Gabriel Gurgel, MSc

Giorgia Tiozzo, MSc

Giorgia Tiozzo, MSc

Tjeerd Looman, MSc

Tjeerd Looman, MSc

Services used

Health economic modeling Evidence synthesis
View all cases

Do you have a question? just asc